United States - English - NLM (National Library of Medicine)

xellia pharmaceuticals aps - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - polymyxin b 500000 - acute infections caused by susceptible strains of pseudomonas aeruginosa. polymyxin b sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of ps. aeruginosa . it may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of ps. aeruginosa . it may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: h influenzae , specifically meningeal infections. escherichia coli , specifically urinary tract infections. aerobacter aerogenes , specifically bacteremia. klebsiella pneumoniae , specifically bacteremia. note: in meningeal infections, polymyxin b sulfate should be administered only by the intrathecal route. to reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin b and other antibacterial drugs, polymyxin b should be used

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin sulfate 500 mg

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin sulfate 500 mg

Malta - English - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - colistin mesilate, sodium - powder and solvent for solution for infusion or injection - colistin mesilate sodium 1000000 iu - antibacterials for systemic use

Canada - English - Health Canada

marcan pharmaceuticals inc - amikacin (amikacin sulfate) - solution - 500mg - amikacin (amikacin sulfate) 500mg - aminoglycosides

Canada - English - Health Canada

omega laboratories limited - amikacin (amikacin sulfate) - solution - 250mg - amikacin (amikacin sulfate) 250mg - aminoglycosides

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - amikacin sulfate, quantity: 333.76 mg/ml (equivalent: amikacin, qty 250 mg/ml) - injection, solution - excipient ingredients: sodium citrate; water for injections; sulfuric acid; sodium metabisulfite - amiwok is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see microbiology).,staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of stapylococcus who have failed to respond or are allergic to other available antibiotics.,amiwok is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, post- operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - amikacin sulfate, quantity: 333.76 mg/ml (equivalent: amikacin, qty 250 mg/ml) - injection, solution - excipient ingredients: sodium citrate; water for injections; sulfuric acid; sodium metabisulfite - amikacin wockhardt is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see microbiology).,staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of stapylococcus who have failed to respond or are allergic to other available antibiotics.,amikacin wockhardt is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, post- operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - gentamicin sulfate, quantity: 16.13 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections; sulfuric acid; sodium hydroxide - indications as at 31 october 2003: gentamicin injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: pseudomonas aeruginosa, proteus species (indole positive and indole negative), escherichia coli, klebsiella - enterobacter - serratia species, staphylococcus species (coagulase positive and coagulase negative). gentamicin injection should be considered for the treatment of the following conditions when caused by susceptible organisms: septicaemia, respiratory tract infections, infected wounds, bone and soft tissue infections including peritonitis, septic abortion and burns complicated by sepsis, urinary tract infections (recurrent, complicated). gentamicin injection is not routinely indicated in the initial treatment of uncomplicated urinary tract infections unless the organism is resistant to other less toxic antibacterials. gentamicin injection may be considered as initial therapy in suspected or confirmed gram negative infections and ther

United States - English - NLM (National Library of Medicine)

hospira, inc. - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. gentamicin sulfate injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: pseudomonas aeruginosa , proteus species (indole-positive and indole-negative), escherichia coli , klebsiella-enterobacter-serratia species, citrobacter species, and staphylococcus species (coagulase-positive and coagulase-negative). clinical studies have shown gentamicin sulfate injection, usp to be effective in bacterial neonatal se